Trial Profile
An Exploratory, Open-label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis